文献速递类风湿关节炎

类风湿关节炎难治性病程的风险预测

Risk profiling for a refractory course of rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2019-02-08

该研究基于纵向临床数据库,比较难治性类风湿关节炎(reRA)与治疗反应良好者(taRA),发现女性、首次就诊时较高CDAI及治疗延迟是难治性病程的独立预测因素,并据此构建风险矩阵模型。

要点

  • 治疗延迟是难治性RA唯一最重要的可干预危险因素。
  • 女性、首次就诊高疾病活动度及治疗延迟为独立预测因素。
  • 基于上述因素构建的矩阵模型可用于未来难治风险分层。

核心结论

  • 治疗延迟、女性性别和较高疾病活动度是类风湿关节炎后期难治性病程的重要预测因素,其中治疗延迟是唯一最重要的可干预危险因素。

研究设计与样本

  • 纵向学术临床数据库研究,纳入412例患者,其中难治性RA(reRA)70例、治疗反应良好RA(taRA)102例,240例不符合任一标准。
  • 采用逻辑回归分析识别难治性疾病危险因素,并针对reRA不同潜在定义进行敏感性分析,关键发现在独立社区队列中验证。

主要发现

  • reRA患者女性比例更高(92.9% vs 70.6%,p < 0.001)。
  • reRA患者更年轻(44.37 vs 51.14岁,p = 0.002)。
  • reRA患者首次就诊时CDAI更高(26.06 vs 15.39,p < 0.001)。
  • reRA患者治疗延迟显著长于taRA(3.17 vs 1.45年,p = 0.001)。
  • 多变量分析中,治疗延迟、女性性别和较高疾病活动度仍为难治性疾病的独立预测因素。

关键数值与推荐

  • reRA定义为:在≥18个月内、≥3种DMARD方案(包括≥1种生物制剂)治疗后仍未达到至少低疾病活动度的治疗目标。
  • taRA定义为:在前两种治疗内即产生应答。

临床怎么用

  • 对具有女性、高疾病活动度及治疗延迟特征的患者应尽早识别并积极干预,以降低未来难治性病程风险。
  • 基于治疗延迟、性别和疾病活动度的矩阵模型可用于难治性RA的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite modern therapeutics and treatment strategies, a subset of rheumatoid arthritis (RA) patients remains insufficiently responsive to multiple therapies. Here, we identify predictors of such refractory RA ("reRA"). METHODS: Patients from a longitudinal academic clinical database with reRA (defined as failing to reach the treatment target of at least low disease activity with ≥3 DMARD courses, including ≥1 biological, over a total of ≥18 months) were compared to patients who did respond within the first two treatments (treatment amenable RA, "taRA"). We performed logistic regression analysis to identify risk factors for refractory disease, and several sensitivity analyses concerning different potential definitions for reRA to confirm the robustness of the results; key findings were also validated in an independent community cohort. RESULTS: We enrolled 412 patients, of whom 70 were reRA and 102 taRA; 240 patients fulfilled neither definition. ReRA patients were more frequently female (92.9 vs. 70.6%, p < 0.001), younger (44.37 vs. 51.14 years, p = 0.002), and had higher CDAI levels at first presentation (26.06 vs. 15.39, p < 0.001). Treatment delay was significantly longer for reRA than for taRA (3.17 vs. 1.45 years, p = 0.001). In multivariable analyses, treatment delay, female gender and higher disease activity remained as independent predictors of refractory disease. Based on the identified predictors, we developed a matrix model for risk of future reRA. CONCLUSIONS: Our data identified delay to initial treatment, female gender and higher disease activity as important predictors of a later refractory course of RA. Delay of treatment initiation is the single most important modifiable risk factor of refractory disease.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Bécède M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 30799033. doi:10.1016/j.semarthrit.2019.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。